Suven Life gets patent for neuro-degenerative drug
New Delhi: Drug firm Suven Life Sciences has been granted a patent each by Europe, Hong Kong, Japan, Macau, ARIPO and South Korea for a neuro degenerative drug used in the treatment of neuro degenerative diseases.
In a BSE filing today, Suven Life said: "They secured product patents in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea to their New Chemical Entities (NCEs) for CNS therapy."
The patents are valid till 2031, the company added.
Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."
With these new patents, Suven has a total of 1 granted patent from ARIPO (African Regional Intellectual Property Organisation), 19 from Europe, 18 from Hong Kong, 18 from Japan, 7 from Macau and 18 from South Korea.
"These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II," Suven said.
In a BSE filing today, Suven Life said: "They secured product patents in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea to their New Chemical Entities (NCEs) for CNS therapy."
The patents are valid till 2031, the company added.
Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."
With these new patents, Suven has a total of 1 granted patent from ARIPO (African Regional Intellectual Property Organisation), 19 from Europe, 18 from Hong Kong, 18 from Japan, 7 from Macau and 18 from South Korea.
"These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II," Suven said.
Next Story
